Marrow graft rejection and veno-occlusive disease of the liver in patients with aplastic anemia conditioned with cyclophosphamide and cyclosporine

H. Joachim Deeg, Howard M. Shulman, Elizabeth Schmidt, Gary C. Yee, E. Donnall Thomas, Rainer Storb

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Based on studies in multiply transfused dogs showing that cyclosporine (CsA) pregrafting reduced the incidence of rejection, we treated 11 multiply transfused patients with severe aplastic anemia with CsA, 12.5–20 mg/kg/day i.m. on days-6 to-1, and cyclophosphamide, 50 mg/kg/day i.v. on days −5 to −2, followed on day 0 by a marrow graft from an HLA-identical sibling donor. Patients were not given additional infusions of buffy coat cells from their marrow donors. As postgrafting prophylaxia for graft-versus-host disease 10 patients were give CsA, 12.5 mg/kg/day orally, and one patient was given a standard regimen of intermittent method

Original languageEnglish (US)
Pages (from-to)497-501
Number of pages5
JournalTransplantation
Volume42
Issue number5
DOIs
StatePublished - Nov 1986

ASJC Scopus subject areas

  • Transplantation

Fingerprint Dive into the research topics of 'Marrow graft rejection and veno-occlusive disease of the liver in patients with aplastic anemia conditioned with cyclophosphamide and cyclosporine'. Together they form a unique fingerprint.

  • Cite this